Compare Nutanix Inc (NTNX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nutanix Inc trades at $54 (market cap $14.90B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Nutanix Inc is far larger — about 9.7× Recursion Pharmaceuticals Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NTNX | RXRX | |
|---|---|---|
Market Cap | $14.90B | $1.53B |
Sector | Technology | Health |
52-Week High | $81.12 | $6.79 |
52-Week Low | $34.41 | $2.84 |
Enterprise Value | $14.41B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $55.11, up slightly by 0.05% today, with a bullish technical trend and strong analyst support. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue growth is projected to rise from $2.54 billion in 2025 to $2.7 billion in 2026, while net income margin improves to 10.03%. Recent news highlights partnerships and NVIDIA certification for its storage solutions, reinforcing its hybrid cloud positioning.
The outlook for NTNX is positive, driven by earnings momentum and strategic initiatives in AI infrastructure. Investment opportunities include potential upside to the $57.80 consensus price target and expanding profit margins. Key risks involve competitive pressures in cloud computing and reliance on enterprise spending cycles, which could impact growth if macroeconomic conditions weaken.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
